Experimental immune therapy aims to reduce deaths in severe pneumonia

NCT ID NCT07615010

Recruiting now Disease control Sponsor: MiNK Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 2 times

Summary

This study tests whether a single dose of an experimental immune cell therapy called agenT-797, given alongside standard care, can lower the risk of death in adults with severe pneumonia and breathing failure. About 90 people in intensive care will receive either agenT-797 or a placebo, plus usual treatments like antibiotics and steroids. The main goal is to see if more people survive with the added therapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: agenT-797 (an experimental immune cell therapy given as a single intravenous infusion)
What this could lead to: If it works, this could point toward a new treatment to reduce deaths from severe pneumonia with respiratory failure.
What could go wrong: This is a small, early Phase 2 trial with only 90 participants, so results may not apply broadly. The treatment is experimental and may not improve survival or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE RESPIRATORY DISTRESS SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute respiratory distress syndrome pneumonia respiratory failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PNEUMONIA

Contacts and locations

Locations

Children's Memorial Hermann Hospital
NOT_YET_RECRUITING

Houston, Texas, 77030, United States
First Lviv Territorial Medical Union
RECRUITING

Lviv, 79059, Ukraine
UCSF Medical Center at Parnassus Heights
NOT_YET_RECRUITING

San Francisco, California, 94143, United States
University Hospital
NOT_YET_RECRUITING

San Antonio, Texas, 78229, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.